Developing treatments for
HPV infection and related cancers

State-of-the-art immunotherapy

EXECUTIVE SUMMARY

HPV causes 5% of
all human cancers

Cervical cancer
Head and neck cancer
Anal cancer
Genital cancers (vaginal, vulvar, penile)

EXECUTIVE SUMMARY

HPV causes 99%
of cervical cancers

No woman should die from cervical cancer
Get vaccinated
Get screened

EXECUTIVE SUMMARY
PapiVax is a biotechnology company focused on immunotherapy for chronic viral infections and related cancers with Phase II assets in HPV infection and in HPV-related cancers.

PapiVax Biotech, Inc. (PBI) is a biotechnology company that intends to become a global leader in immunotherapy for chronic viral infections and related cancers…

read more

PBI’s primary technology uses self-adjuvanting DNA vaccines administered with a heterologous booster immunization to achieve a safe and effective immunotherapeutic response.

read more

Human papillomavirus (HPV) is the most common sexually transmitted infection and is linked to nearly all (approximately 99%) cervical cancer cases in women and 4.5% of all cancers worldwide.

read more

PBI seeks to engage all stakeholders in our mission through presentations at many venues, and news releases on diverse media.

read more

Top